However, to further isolate the effect of tamoxifen on PIK3CA mutation frequencies, we also compared clinicogenomic TA-UCs with a unique cohort of de novo UC from patients with breast cancer never treated with tamoxifen. This evidence concerns the gene PIK3CA and breast cancer.